Expression of CA125 in Tissue and Serum of Uterine Serous Carcinoma Patients

Abstract

Uterine serous carcinoma (USC) represents only about 10% of endometrial cancer cases. It is an aggressive tumor with a poor prognosis that is diagnosed in advanced stages in about 40% of the cases and it accounts for a disproportionate number of uterine cancer-related deaths. Even in apparent clinical early stage disease, USC is found to have unfavorable pathological prognostic factors such as lymphovascular space invasion, lymph node involvement, and microscopic intraperitoneal spread [1,2].